Modeling the economic burden of adult vaccine-preventable diseases in the United States

Health Affairs

Volumn 35, Issue 11, 2016, Pages 2124-2132

  Ozawa, Sachiko ^a   Portnoy, Allison ^b   Getaneh, Hiwote ^c   Clark, Samantha ^d   Knoll, Maria ^d   Bishai, David ^d   Yang, H Keri ^e   Patwardhan, Pallavi D ^e  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MDRC   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ARTICLE; CHICKENPOX; COST OF ILLNESS; DATA BASE; DIPHTHERIA; HEALTH CARE COST; HEALTH CARE PLANNING; HEPATITIS A; HEPATITIS B; HERPES ZOSTER; HUMAN; IMMUNIZATION; INFLUENZA; MEASLES; MENINGOCOCCOSIS; MUMPS; PAPILLOMAVIRUS INFECTION; PATIENT AUTONOMY; PERTUSSIS; PNEUMOCOCCAL INFECTION; PROGRAM DEVELOPMENT; RUBELLA; TETANUS; UNITED STATES; ADULT; COMMUNICABLE DISEASE; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; HOSPITALIZATION;

ADULT; COMMUNICABLE DISEASES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MODELS, ECONOMIC; UNITED STATES; VACCINES;

EID: 84995921661     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2016.0462     Document Type: Article

References (30)

1. Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med. 2006;31(1):72-9.
2. Centers for Disease Control and Prevention. Flu vaccination coverage, United States, 2015-16 influenza season [Internet]. Atlanta (GA): CDC; 2016 Sep 29 [cited 2016 Oct 3]. Available from: http://www.cdc.gov/flu/fluvaxview/coverage-1516estimates.htm
3. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25(27): 5086-96.
4. Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged =50 years. Vaccine. 2012;30(36):5437-44.
5. Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine. 2010;28(31):4955-60.
6. Huang SS, Johnson KM, Ray GT, Wroe P, Lieu TA, Moore MR, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011;29(18):3398-412.
7. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013;369(2): 155-63.
8. Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10(9):e1001517.
9. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301-9.
10. Knoll M, Clark S, Portnoy A, Roberts C, Ozawa S. Preliminary estimates of adult pneumococcal disease burden in the United States in the post 13-valent pneumococcal conjugate vaccine (PCV-13) era. Paper presented at: 10th International Symposium on Pneumococci and Pneumococcal Diseases; 2016 Jun 26-30; Glasgow, Scotland.
11. Hodgson TA. Costs of illness in costeffectiveness analysis. A review of the methodology. Pharmacoeconomics. 1994;6(6):536-52.
12. Hodgson TA, Meiners MR. Cost-ofillness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc. 1982;60(3):429-62.
13. Helmecke MR, Elmendorf SL, Kent DL, Pauze DK, Pauze DR. Measles investigation: a moving target. Am J Infect Control. 2014;42(8):911-5.
14. Healthcare Cost and Utilization Project. Overview of the National (Nationwide) Inpatient Sample (NIS) [Internet]. Rockville (MD): Agency for Healthcare Research and Quality; 2011 [cited 2016 Sep 19]. Available from: http://www.hcup-us.ahrq.gov/nisoverview.jsp
15. Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey (MEPS) [Internet]. Rockville (MD): AHRQ; 2011 [cited 2016 Sep 19]. Available from: http://www.ahrq.gov/research/data/meps/index.html
16. Cameron TA, DeShazo JR. Demand for health risk reductions. J Environ Econ Manage. 2013;65(1):87-109.
17. Hammitt JK, Robinson LA. The income elasticity of the value per statistical life: transferring estimates between high and low income populations. JBCA [serial on the Internet]. 2011;2(1):Article 1 [cited 2016 Sep 28]. Available from: http://www.regulatory-analysis.com/hammittrobinson-VSL-income-elasticity.pdf
18. Robinson LA. Valuing mortality risk reductions in homeland security regulatory analyses. Washington (DC): Department of Homeland Security, Customs and Border Protection; 2008 Jun.
19. Robinson LA, Hammitt JK. Behavioral economics and regulatory analysis. Risk Anal. 2011;31(9): 1408-22.
20. Rubin PH. The FDA's antibiotic resistance. Regulation. 2004;27(4): 34-7.
21. Viscusi WK. The value of life: estimates with risks by occupation and industry. Cambridge (MA): Harvard Law School; 2003 May.
22. Viscusi WK, Aldy JE. The value of a statistical life: a critical review of market estimates throughout the world. J Risk Uncertain. 2003;27(1): 5-76.
23. Viscusi WK, Hersch J. The mortality cost to smokers. J Health Econ. 2008;27(4):943-58.
24. Environmental Protection Agency. Mortality risk valuation: what is the "value of a statistical life"? [Internet]. Washington (DC): EPA; [last updated 2016 May 27; cited 2016 Sep 28]. Available from: https://www.epa.gov/environmentaleconomics/mortality-risk-valuation
25. Briggs A, Gray A. The distribution of health care costs and their statistical analysis for economic evaluation. J Health Serv Res Policy. 1998;3(4): 233-45.
26. Williams WW, Lu PJ, Lindley MC, Kennedy ED, Singleton JA. Influenza vaccination coverage among adults-National Health Interview Survey, United States, 2008-09 influenza season. MMWR Suppl. 2012;61(2): 65-72.
27. McLaughlin JM, McGinnis JJ, Tan L, Mercatante A, Fortuna J. Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013. J Prim Prev. 2015;36(4):259-73.
28. Miller MA, Redd S, Hadler S, Hinman A. A model to estimate the potential economic benefits of measles eradication for the United States. Vaccine. 1998;16(20):1917-22.
29. Shim E, Grefenstette JJ, Albert SM, Cakouros BE, Burke DS. A game dynamic model for vaccine skeptics and vaccine believers: measles as an example. J Theor Biol. 2012;295: 194-203.
30. Hornberger J, Robertus K. Costeffectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006;145(5):317-25.